Finally our academic POC CD19 #CARTcell investigator initiated phase 1-2 trial for adults with ALL has been approved!
Evidence that it IS possible to conduct IITs in Latin America.
Hoping to start enrolling 🔜
This case highlights the critical role of immunosuppressive therapy, especially in resource-limited settings where newer treatments like caplacizumab aren't readily available.
@BloodCellsByAle@paulo_ug#Hematology#TTP#GlobalHealth 🩸🩸
Low-dose rituximab was started. ADAMTS13 activity was <10%, confirming a-TTP. A hematologic response has been maintained for >72 hours with rituximab and steroids.
Case of the week🕵️♂️🔎
A 24y-old👩🏽 presented with fatigue, headache, diarrhea, and myalgias. Labs showed hemolysis with schistocytes on 🔬PLASMIC score of 6 suggested a high likelihood of TTP. PEX & steroids were initiated, but she developed recurrent anaphylaxis during PEX🚨